Overview

Pegylated Liposomal Doxorubicin and Carboplatin as First Line Treatment for Patients With Advanced Non-small Cell Lung Cancer

Status:
Unknown status

Trial end date:
2011-11-01

Target enrollment:

Participant gender:

Summary

This Phase II study is to explore the efficacy and toxicity of Pegylated liposomal doxorubicin and Carboplatin in patients with previously untreated non-small cell lung cancer (NSCLC) not amenable to radiotherapy or surgical treatment. The planned enrollment for this trial is 48 patients (including a 10% rate for inevaluable patients).

Phase:

Phase 2

Details

Lead Sponsor:

The First Affiliated Hospital of Guangzhou Medical University

Treatments:

Carboplatin
Doxorubicin
Liposomal doxorubicin